← Back
Cytosorbents
CTSO · listed on Nasdaq · worth $12.95 million
$4.54
−9.25% on Nov 2
Nine insider buys in the last year, $199.3K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
Reverse split 1-for-20 in Sep 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what CTSO ever actually traded at. The drop is real, but those huge old numbers aren't.
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
2.8M shares
88% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought Cytosorbents stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Executive Officer
Phillip P. Chan
Bought $100.5K on Jun 12 — 251,136 shares at $0.4000, 15% of what they now own.
No earlier purchases to measure
Chief Financial Officer
Peter J. Mariani
Bought $44K on Jun 15 — 100,000 shares at $0.4400, 16% of what they now own.
No earlier purchases to measure
Director
Alan D. Sobel
Bought $11.6K on Sep 15 — 1,900 shares at $6.12, 21% of what they now own.
No earlier purchases to measure
All reports
Every insider trade and SEC report we hold for Cytosorbents.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
4 more with Pro →Analysts, earnings and news
Analysts' price target
$2.88 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 4 quarters above
Q1 '26−$0.08 a share−$0.03
Q4 '25−$0.09 a share−$0.04
Q3 '25−$0.05 a share−$0.00
Q2 '25$0.03 a share+$0.09